Deaths / year
0
GBD (indicative unless refreshed)
DALYs / year
200,000
GBD
Pathogen
Bacteria
Post-infectious
Lasting sequela
Persistent symptoms
n/a
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Post-acute status
Conjunctival scarring -> trichiasis -> irreversible blindness
Classification
Lasting sequela
Onset
chronic/late
Persistent-symptom %
not quantified as a single figure (see notes)
Source: WHO trachoma (SAFE)
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Prevention
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Facial cleanliness & environmental improvement (F&E) | Prevention | Approved | WHO SAFE strategy — hygiene/environment arm | WHO EML / standard of care |
| Azithromycin (mass drug administration) | Antibiotic | Approved | WHO SAFE strategy — antibiotic arm | WHO EML / standard of care |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Tetracycline eye ointment | Antibiotic | Approved | Alternative topical treatment | WHO EML / standard of care |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Trichiasis surgery | Surgical | Approved | SAFE surgery component for trichiasis | WHO trachoma |
Associated drug targets (Open Targets): SLC35A2, CXCL8, KLRC2, MMP9, HSPD1, TNF
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: MONDO_0005808 · Updated 2026-07-10. Associations, not a diagnostic test.